Metformin in the treatment of type 2 diabetes mellitus and its current position

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2024; 24(1): 21-23
Category:

Overview

Over the past two decades, the cost of treating type 2 diabetes mellitus (T2DM) has increased dramatically, and a greater financial burden is being passed on to T2DM patients and their families [1]. Medication co-payments can be a major source of stress for people with T2DM and contribute to poorer medication use [2]; in many cases, cost reduction strategies can improve treatment as well as patient behavior [3]. Metformin is still recommended as a first-line antidiabetic treatment for patients with T2DM because of its relatively high efficacy to modify glycaemia and HbA_1c and other benefits.

Keywords:

HbA1c – glycemia – type 2 diabetes mellitus (T2DM)

Sources

Riddle MC, Herman WH. The cost of diabetes care – an elephant in the room. Diabetes Care 2018; 41(5): 929–932. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0012>.

Kang H, Lobo JM, Kim S et al. Cost related medication non-adherence among U.S. adults with diabetes. Diabetes Res Clin Pract 2018; 143: 24–33. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2018.06.016>.

Patel MR, Piette JD, Resnicow K et al. Social determinants of health, cost-related nonadherence, and cost reducing behaviors among adults with diabetes: findings from the National Health Interview Survey. Med Care 2016; 54(8): 796–803. Dostupné z DOI: <http://dx.doi.org/10.1097/MLR.0000000000000565>.

Martinka E, Tkáč I, Mokáň M et al. Odporúčané postupy pre liečbu diabetes mellitus 2. typu – 2023. Forum Diab 2023; 12(2): 93–133.

Maruthur NM, Tseng E, Hutfless S et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164(11): 740–751. Dostupné z DOI: <http://dx.doi.org/10.7326/M15–2650>.

[U.S. Food and Drug Administration]. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2017. Dostupné z WWW: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain>.

Out M, Kooy A, Lehert P et al. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial. J Diabetes Complications 2018; 32(2): 171–178. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2017.11.001>.

Aroda VR, Edelstein SL, Goldberg RB et al. [Diabetes Prevention Program Research Group]. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101(4): 1754–1761. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015–3754>.

Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care 2016; 39(Suppl 2): S137–S145. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS15–3007>.